MAXIMIZING ONCOLOGY ANALYSIS WITH BUILT-IN KRAS ASSAY PROVIDERS AND RAS ASSAYS

during the fast evolving industry of oncology study, correct and economical mutation screening is vital for building specific therapies. The KRAS providers Platform plays a pivotal position During this landscape by giving thorough alternatives for KRAS mutation profiling and analysis. KRAS mutations, found in approximately ninety five% of RAS-assoc